AMILORIDE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H8ClN7O.ClH.2H2O
Molecular Weight	302.119
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.Cl.NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1

InChI

InChIKey=LTKVFMLMEYCWMK-UHFFFAOYSA-N

InChI=1S/C6H8ClN7O.ClH.2H2O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11;;;/h(H4,8,9,13)(H4,10,11,14,15);1H;2*1H2

HIDE SMILES / InChI

Molecular Formula	C6H8ClN7O
Molecular Weight	229.627
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00594
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-200S024_Midamor_Prntlbl.pdf

Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. It is used for as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amiloride-sensitive sodium channel alpha-subunit 5 Target ID: CHEMBL1791 Sources: http://www.drugbank.ca/drugs/DB00594	Inhibitor 8297	776.0 nM [IC50]
Amiloride-sensitive sodium channel subunit beta 3 Target ID: P51168 Gene ID: 6338.0 Gene Symbol: SCNN1B Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00594	Inhibitor 8297
Amiloride-sensitive sodium channel subunit gamma 3 Target ID: P51170\|\|\|Q96TD2 Gene ID: 6340.0 Gene Symbol: SCNN1G Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00594	Inhibitor 8297
Amiloride-sensitive cation channel 3 3 Target ID: CHEMBL5368 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19339181	Inhibitor 8297	4.4 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-200S024_Midamor_Prntlbl.pdf	Primary		Approved 8429	Midamor Approved Use Preventing development of low blood potassium or helping to restore normal blood potassium in patients with high blood pressure or heart failure. Launch Date 1981
Heart failure 103 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-200S024_Midamor_Prntlbl.pdf	Primary		Approved 8429	Midamor Approved Use Preventing development of low blood potassium or helping to restore normal blood potassium in patients with high blood pressure or heart failure. Launch Date 1981

C_max

Value	Dose	Co-administered	Analyte	Population
20.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9085317	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMILORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1.57 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9085317	17 mmol single, respiratory dose: 17 mmol route of administration: Respiratory experiment type: SINGLE co-administered:		AMILORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
275 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9085317	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMILORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
16 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9085317	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMILORIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
77% DRUG LABEL https://reference.medscape.com/drug/midamor-amiloride-342406#10			AMILORIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg 3 times / day multiple, oral Highest studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6386025 Page: p.372	healthy, 25-44 n = 5 Health Status: healthy Age Group: 25-44 Sex: M Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/6386025 Page: p.372	Sources: https://pubmed.ncbi.nlm.nih.gov/6386025 Page: p.372
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: furosemide, p.o(40 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696	unhealthy, 58 n = 18 Health Status: unhealthy Condition: Hypertension Age Group: 58 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696	Disc. AE: Dry mouth, Constipation... AEs leading to discontinuation/dose reduction: Dry mouth (5.5%) Constipation (5.5%) Malaise (moderate, 5.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696
5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Co-administed with:: hydrochlorothiazide, p.o(50 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423	unhealthy n = 12 Health Status: unhealthy Condition: Hypertension Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423	Disc. AE: Nausea, Weakness... AEs leading to discontinuation/dose reduction: Nausea (severe, 16.7%) Weakness (severe, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423

AEs

AE	Significance	Dose	Population
Constipation	5.5% Disc. AE	10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: furosemide, p.o(40 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696	unhealthy, 58 n = 18 Health Status: unhealthy Condition: Hypertension Age Group: 58 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696
Dry mouth	5.5% Disc. AE	10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: furosemide, p.o(40 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696	unhealthy, 58 n = 18 Health Status: unhealthy Condition: Hypertension Age Group: 58 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696
Malaise	moderate, 5.5% Disc. AE	10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: furosemide, p.o(40 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696	unhealthy, 58 n = 18 Health Status: unhealthy Condition: Hypertension Age Group: 58 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/3371085 Page: p.696
Nausea	severe, 16.7% Disc. AE	5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Co-administed with:: hydrochlorothiazide, p.o(50 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423	unhealthy n = 12 Health Status: unhealthy Condition: Hypertension Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423
Weakness	severe, 16.7% Disc. AE	5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Co-administed with:: hydrochlorothiazide, p.o(50 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423	unhealthy n = 12 Health Status: unhealthy Condition: Hypertension Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/5639627 Page: p.423

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Cav3.1 7 Cav3.2 12 Cav3.3 7 MATE1 306 MATE2 263 OCT1 512 OAT4 146	MATE1 135 MATE2 96 OCT1 327 OCT2 355

Drug as perpetrator

Target	Modality	Activity
OAT4 146	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17229912/	likely
Cav3.3 7	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22767612/	weak [IC50 1091 uM]
Cav3.1 7	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22767612/	weak [IC50 840 uM]
MATE1 308	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22419765/	yes [IC50 2.41 uM]
MATE2 263	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22419765/	yes [IC50 3.06 uM]
Cav3.2 12	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22767612/	yes [IC50 62 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	yes

Drug as victim

Target	Modality	Activity
MATE1 135	substrate 3367 Sources: http://www.slib.agu.ac.jp/gakukaisi/pdf/y12_22.pdf	yes
MATE2 96	substrate 3367 Sources: http://www.slib.agu.ac.jp/gakukaisi/pdf/y12_22.pdf	yes
OCT1 327	substrate 3367 Sources: http://www.slib.agu.ac.jp/gakukaisi/pdf/y12_22.pdf	yes
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16394027/\|http://www.slib.agu.ac.jp/gakukaisi/pdf/y12_22.pdf	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2639	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2639
ChemicalBook	CB7146512	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7146512
ZINC	ZINC000004340269	http://zinc15.docking.org/substances/ZINC000004340269
eMolecules	1934607	https://www.emolecules.com/cgi-bin/more?vid=1934607

PubMed

Title	Date	PubMed
Acute effects of lithium on the renal concentrating mechanism in a primate.	1975 Mar	1115255
Influence of ammonia on sodium absorption in rat proximal colon.	2000 Aug	10958346
Transepithelial resistance can be regulated by the intestinal brush-border Na(+)/H(+) exchanger NHE3.	2000 Dec	11078707
The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure.	2001	11293648
Impaired sodium excretion, decreased glomerular filtration rate and elevated blood pressure in endothelin receptor type B deficient rats.	2001	11269510
Tracing the route taken by peptides and major histocompatibility complex class I molecules in presentation of exogenous antigens.	2001	11068748
Maxi K+ channels co-localised with CFTR in the apical membrane of an exocrine gland acinus: possible involvement in secretion.	2001 Apr	11374055
Regulation of Na(+) transport across leech skin by peptide hormones and neurotransmitters.	2001 Apr	11273812
Effects of SNP, ouabain, and amiloride on electrical potential profile of isolated sheep pleura.	2001 Apr	11247961
Expression of highly selective sodium channels in alveolar type II cells is determined by culture conditions.	2001 Apr	11238004
Involvement of noradrenaline transporters in S-nitrosocysteine-stimulated noradrenaline release from rat brain slices: existence of functional Na(+)-independent transporter activity.	2001 Apr	11137627
Oxygen-evoked Na+ transport in rat fetal distal lung epithelial cells.	2001 Apr 1	11283228
Effect of 2',4'-dichlorobenzamil hydrochloride, a Na(+)-Ca(2+) exchange inhibitor, on human spermatozoa.	2001 Apr 20	11334878
Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films.	2001 Feb	11182377
Pontine gustatory activity is altered by electrical stimulation in the central nucleus of the amygdala.	2001 Feb	11160511
Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study.	2001 Feb	11159895
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Activation of Na(+), K(+), Cl(-)-cotransport mediates intracellular Ca(2+) increase and apoptosis induced by Pinacidil in HepG2 human hepatoblastoma cells.	2001 Feb 23	11181077
Involvement of calcium influx in hypoxia-induced bleb formation in human umbilical vein endothelial cells.	2001 Feb-Mar	11267120
Transport of [3H]MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4).	2001 Jan	11191826
Magnesium transport in the renal distal convoluted tubule.	2001 Jan	11152754
Effects of enzyme and anion transport inhibitors on in vitro incorporation of inorganic carbon and calcium into endolymph and otoliths in salmon Oncorhynchus masou.	2001 Jan	11137450
Functional role of sodium-calcium exchange in the regulation of renal vascular resistance.	2001 Jan	11133525
NHE and ICAM-1 expression in hypoxic/reoxygenated coronary microvascular endothelial cells.	2001 Jun	11356638
cAMP-dependent fluid secretion in rat inner medullary collecting ducts.	2001 Jun	11352842
Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium.	2001 Jun	11350806
NaCl detection thresholds: comparison of Fischer 344 and Wistar rats.	2001 Mar	11287385
New quinolone, grepafloxacin, inhibits Cl- secretion across bovine airway epithelium in culture.	2001 Mar	11264763
Complexities of measuring antagonist potency at P2X(7) receptor orthologs.	2001 Mar	11181928
The distal convoluted tubule of rabbit kidney does not express a functional sodium channel.	2001 Mar	11181416
Alveolar epithelial barrier functions in ventilated perfused rabbit lungs.	2001 May	11290513
Nongenomic effect of testosterone on chloride secretion in cultured rat efferent duct epithelia.	2001 May	11287329
Dependence of the acid-sensitive ion channel, ASIC1a, on extracellular Ca(2+) ions.	2001 May 11	11334808
Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network.	2001 May 18	11279194
A standing Na+ conductance in rat carotid body type I cells.	2001 May 25	11388422
Amiloride-sensitive sodium currents in identified taste cells of the frog.	2001 May 25	11388403

Patents

Sample Use Guides

In Vivo Use Guide

MIDAMOR (Amiloride), one 5 mg tablet daily, should be added to the usual antihypertensive or diuretic dosage of a kaliuretic diuretic. The dosage may be increased to 10 mg per day, if necessary. More than two 5 mg tablets of MIDAMOR daily usually are not needed, and there is little controlled experience with such doses. If persistent hypokalemia is documented with 10 mg, the dose can be increased to 15 mg, then 20 mg, with careful monitoring of electrolytes. If it is necessary to use MIDAMOR alone (see INDICATIONS), the starting dosage should be one 5 mg tablet daily. This dosage may be increased to 10 mg per day, if necessary. More than two 5 mg tablets usually are not needed, and there is little controlled experience with such doses. If persistent hypokalemia is documented with 10 mg, the dose can be increased to 15 mg, then 20 mg, with careful monitoring of electrolytes.

Route of Administration: Oral

In Vitro Use Guide

Amiloride (10, 30, and 100 μmol/L) concentration-dependently potentiated erlotinib-induced inhibition of cell proliferation and colony formation in the 4 human pancreatic cancer cell lines.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:23:05 GMT 2023` Edited by `admin` on `Fri Dec 15 17:23:05 GMT 2023`
Record UNII	FZJ37245UC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMILORIDE HYDROCHLORIDE

Official Name

English

NSC-755847

Code

English

AMILORIDE HYDROCHLORIDE COMPONENT OF MODURETIC

Common Name

English

AMILORIDE HYDROCHLORIDE DIHYDRATE [MI]

Common Name

English

AMILORIDE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

AMILORIDE HYDROCHLORIDE [USP-RS]

Common Name

English

AMILORIDE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

AMILORIDE HYDROCHLORIDE [EP IMPURITY]

Common Name

English

Amiloride hydrochloride dihydrate [WHO-DD]

Common Name

English

AMILORIDE HCL

Common Name

English

AMILORIDE HYDROCHLORIDE [USAN]

Common Name

English

AMILORIDE HYDROCHLORIDE COMPONENT OF HYDRO-RIDE

Common Name

English

MODURETIC COMPONENT AMILORIDE HYDROCHLORIDE

Common Name

English

AMILORIDE HYDROCHLORIDE [VANDF]

Common Name

English

PYRAZINECARBOXAMIDE, 3,5-DIAMINO-N-(AMINOIMINOMETHYL)-6-CHLORO-, MONOHYDROCHLORIDE DIHYDRATE

Common Name

English

N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide monohydrochloride dihydrate

Systematic Name

English

AMILORIDE HYDROCHLORIDE [MART.]

Common Name

English

AMILORIDE HYDROCHLORIDE DIHYDRATE

Common Name

English

AMILORIDE HYDROCHLORIDE DEHYDRATE [WHO-IP]

Common Name

English

AMILORIDE HYDROCHLORIDE DIHYDRATE [EP MONOGRAPH]

Common Name

English

MIDAMOR

Brand Name

English

HYDRO-RIDE COMPONENT AMILORIDE HYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C49186

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

FDA ORPHAN DRUG

48190

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

EU-Orphan Drug

EU/3/03/147

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

NCI_THESAURUS

C582

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

Code System Code Type Description

PUBCHEM

68540

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

ChEMBL

CHEMBL945

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

RXCUI

142424

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

RxNorm

CHEBI

84743

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

NSC

755847

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

MERCK INDEX

m1671

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

Merck Index

WHO INTERNATIONAL PHARMACOPEIA

AMILORIDE HYDROCHLORIDE

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

Description: A pale yellow to greenish yellow powder; odourless or almost odourless. Solubility: Slightly soluble in water and ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Diuretic. Storage: Amiloride hydrochloride should be kept in a well-closed container, protected from light. Definition: Amiloride hydrochloride contains not less than 98.0% and not more than 101.0% of C6H8ClN7O,HCl, calculated with reference to the dried substance.

EVMPD

SUB00445MIG

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

FDA UNII

FZJ37245UC

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

DAILYMED

FZJ37245UC

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

EVMPD

SUB21895

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

SMS_ID

100000088483

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

EPA CompTox

DTXSID80169826

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

RS_ITEM_NUM

1019701

Created by admin on Fri Dec 15 17:23:06 GMT 2023 , Edited by admin on Fri Dec 15 17:23:06 GMT 2023

PRIMARY

DRUG BANK

DBSALT001807

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

CAS

17440-83-4

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

NCI_THESAURUS

C47390

Created by admin on Fri Dec 15 17:23:05 GMT 2023 , Edited by admin on Fri Dec 15 17:23:05 GMT 2023

PRIMARY

Related Record Type Details


					FZJ37245UC

AMILORIDE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					7DZO8EB0Z3

AMILORIDE

PARENT -> SALT/SOLVATE


					FZJ37245UC

AMILORIDE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

USP

Amount:


					7M458Q65S3

AMILORIDE HYDROCHLORIDE ANHYDROUS

ANHYDROUS->SOLVATE

Related Record Type Details


					E483J5G69C

3-AMINO-6-CHLORO-N-(DIAMINOMETHYLIDENE)-5-HYDROXYPYRAZINE-2-CARBOXAMIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					4KAT2Q9CHL

METHYL 3,5-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXYLATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					5WS823P8MP

3,5-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXYLIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					7DZO8EB0Z3

AMILORIDE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00594Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-200S024_Midamor_Prntlbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00594
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/18-200S024_Midamor_Prntlbl.pdf

C_max

T_1/2

F_unbound

Drug as perpetrator